Safety Study of MG1102 in Patients With Solid Tumors

Inclusion Criteria:

• 18 years of age or older
• Solid tumors refractory to conventional therapy or the subject does not tolerate the conventional therapy
• Evaluable disease or at least one measurable tumor mass by a radiographic technique
• Life expectancy ≥3 months
• Suitable for intravenous administration of study medication
• Signed written informed consent
• Adequate bone marrow, renal, and liver function
• Coagulation profile with aPTT and INR, each ≤ 1.5 x ULN
• No evidence of active Hepatitis B or Hepatitis C infection
• Proteinuria <100 mg
• ECOG performance status ≤2
• Female subjects must agree to use contraceptive measures
• Negative serum ß-hCG
• Ability and willingness to comply with the study protocol

Exclusion Criteria:

• Pregnant or lactating women
• Therapy with systemic anticoagulant or antithrombotic agentswithin 7 days prior to first dose
• Hemoptysis within 3 months prior to first dose
• Cytotoxic chemotherapy, immunotherapy, or radiotherapy within 4 weeks prior to first dose
• Surgery or visceral biopsy within 28 days prior to first dose
• Minor surgical procedure performed within 7 days prior to first dose
• Prior exposure to MG1102
• Known history of HIV
• With active bacterial infections and/or receiving systemic antibiotics
• Current or past diagnosis of leukemia
• Known CNS metastases or clinical evidence of CNS
• Non-healing wound within past 2 weeks
• Bleeding diathesis or bleeding within 14 days prior to enrollment
• Clinically significant thrombosis
• Non-malignant GI bleeding, gastric stress ulcerations, or peptic ulcer disease
• History of idiopathic or hereditary angioedema
• History of sickle cell or any hemolytic anemia
• Require hemoglobin, WBC, or platelet transfusion support or use of hematopoietic growth factors within 2 weeks prior to entry
• Uncontrolled hypertension
• History of clinically significant renal disease
• History of significant medical illness of cardiac or CNS disease within the past 6 months
• Treatment with an investigational agent within the longest time frame of either 5 half-lives or 30 days of initiating study drug
• Medical or psychiatric illness
• Recreational substance use or psychiatric illness
• Known hypersensitivity to MG1102 or components of the formulation